Aligos Therapeutics, Inc. Financing Cash Flow
Aligos Therapeutics, Inc. (ALGS) reported Financing Cash Flow of $158.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Aligos Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $220.00K.
- Aligos Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$62.00K, a 100.06% decline year-over-year.
- Aligos Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $123.00K, a 26.80% increase year-over-year.
- Aligos Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$53.00K.
- Aligos Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $101.64M, a 28529.58% increase from fiscal 2024.
- Aligos Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $355.00K, a 99.60% decline from fiscal 2023.
- Aligos Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $88.33M, a 53758.54% increase from fiscal 2022.
- Aligos Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $164.00K, a 99.79% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $220.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $158.00K 10-Q · filed 2026-08-06 | $281.00K derived: sum of 3 quarters · filed 2026-08-06 | $228.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$62.00K 10-Q · filed 2026-05-07 | $61.00K derived: sum of 2 quarters · filed 2026-05-07 | $8.00K derived: sum of 3 quarters · filed 2026-05-07 | -$169.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $70.00K derived: sum of 2 quarters · filed 2026-03-05 | -$107.00K derived: sum of 3 quarters · filed 2026-08-06 | $101.64M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$230.00K derived: sum of 2 quarters · filed 2026-08-06 | $101.51M 10-Q · filed 2025-11-06 | $101.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$177.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $101.56M 10-Q · filed 2026-08-06 | $101.66M derived: sum of 3 quarters · filed 2026-08-06 | $101.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $101.74M 10-Q · filed 2026-05-07 | $101.84M derived: sum of 2 quarters · filed 2026-05-07 | $101.83M derived: sum of 3 quarters · filed 2026-05-07 | $102.12M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $93.00K derived: sum of 2 quarters · filed 2026-03-05 | $374.00K derived: sum of 3 quarters · filed 2026-03-05 | $355.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $277.00K derived: sum of 2 quarters · filed 2025-11-06 | $258.00K 10-Q · filed 2025-11-06 | $88.19M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $281.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $262.00K 10-Q · filed 2025-08-06 | $88.20M derived: sum of 3 quarters · filed 2025-08-06 | $88.18M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$19.00K 10-Q · filed 2025-05-06 | $87.92M derived: sum of 2 quarters · filed 2025-05-06 | $87.90M derived: sum of 3 quarters · filed 2025-05-06 | $88.31M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $87.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $87.92M derived: sum of 2 quarters · filed 2025-03-10 | $88.33M derived: sum of 3 quarters · filed 2025-03-10 | $88.33M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $393.00K derived: sum of 2 quarters · filed 2024-11-06 | $392.00K 10-Q · filed 2024-11-06 | $513.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $414.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $413.00K 10-Q · filed 2024-08-06 | $534.00K derived: sum of 3 quarters · filed 2024-08-06 | $515.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$1.00K 10-Q · filed 2024-05-07 | $120.00K derived: sum of 2 quarters · filed 2024-05-07 | $101.00K derived: sum of 3 quarters · filed 2024-05-07 | $184.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $102.00K derived: sum of 2 quarters · filed 2024-03-12 | $185.00K derived: sum of 3 quarters · filed 2024-03-12 | $164.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | -$19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $64.00K derived: sum of 2 quarters · filed 2023-11-02 | $43.00K 10-Q · filed 2023-11-02 | $595.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $62.00K 10-Q · filed 2023-08-03 | $614.00K derived: sum of 3 quarters · filed 2023-08-03 | $78.57M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$21.00K 10-Q · filed 2023-05-04 | $531.00K derived: sum of 2 quarters · filed 2023-05-04 | $78.48M derived: sum of 3 quarters · filed 2023-05-04 | $78.58M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $552.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $78.50M derived: sum of 2 quarters · filed 2023-03-09 | $78.60M derived: sum of 3 quarters · filed 2023-03-09 | $78.68M 10-K · filed 2023-03-09 |
| 2021-09-30 | $77.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $78.05M derived: sum of 2 quarters · filed 2022-11-02 | $78.13M 10-Q · filed 2022-11-02 | $271.44M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $95.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $173.00K 10-Q · filed 2022-08-04 | $193.49M derived: sum of 3 quarters · filed 2022-08-04 | $192.54M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $78.00K 10-Q · filed 2022-05-04 | $193.40M derived: sum of 2 quarters · filed 2022-05-04 | $192.45M derived: sum of 3 quarters · filed 2022-05-04 | $192.47M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $193.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $192.37M derived: sum of 2 quarters · filed 2022-03-10 | $192.40M derived: sum of 3 quarters · filed 2022-03-10 | $192.35M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$949.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$922.00K derived: sum of 2 quarters · filed 2021-11-04 | -$970.00K 10-Q · filed 2021-11-04 | $84.29M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$21.00K 10-Q · filed 2021-08-05 | $85.24M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$48.00K 10-Q · filed 2021-05-10 | $85.22M derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $85.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $85.53M 10-K · filed 2021-03-23 | ||
| 2019-09-30 | $268.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |